---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-016112"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:24:34.723206+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Moleculin Q1 cash $16.8M; Annamycin CRc 62% in 1st/2nd line AML

## Summary
- R&D expense $4.3M, G&A $2.4M; cash $16.8M expected to fund operations into Q4 2024.
- MB-106 trial: 20 subjects evaluated; 45% CRc all lines (N=20); 62% CRc in 1st/2nd line (N=13).
- USPTO issued patent for liposomal Annamycin composition; EMA granted Orphan Drug Designation for AML.
- End of Phase 2 FDA meeting expected H1 2024; pivotal trial initiation planned H1 2025; NDA submission potential 2027.
- Formed Annamycin Scientific Advisory Board with Dr. Martin Tallman as inaugural member.

## SEC filing metadata
- accession: 0001437749-24-016112
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774924016112/0001437749-24-016112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774924016112/mbrx20240509_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-016112
- JSON: https://secwatch.observer/filing/0001437749-24-016112.json
- Plain text: https://secwatch.observer/filing/0001437749-24-016112.txt

## Key facts
- Earnings Releases
  Moleculin Biotech, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 13, 2024, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and recent operational highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774924016112/0001437749-24-016112-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.